Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Frontera London

- PMLiVE

Boehringer Ingelheim and 3T Biosciences in cancer research agreement

The immunotherapy company could receive $268m in milestone payments

- PMLiVE

SCIRIS ANNOUNCES APPOINTMENT OF NEW CEO

Porterhouse extends a very warm welcome to Isaac Batley

Porterhouse Medical Group

Virtual Tools for Promoting Diversity in Pharma and Clinical Trials

It is no secret that Pharma (still) has a major diversity problem.

Impetus Digital

- PMLiVE

IGNIFI ANNOUNCES NEW LEADERSHIP TEAM FOR NEXT PHASE OF GROWTH

Creative healthcare marketing agency IGNIFI has announced its new senior leadership team, which includes the appointment of a new Managing Director for 2023 to lead the business into its next...

IGNIFI

- PMLiVE

Research Partnership appoints new CEO

Research Partnership has appointed Gareth Phillips to take over as CEO

Inizio

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug receives FDA accelerated approval

An application has also been submitted for US approval under the traditional pathway

- PMLiVE

GSK and CureVac to advance mRNA COVID-19 and flu vaccine candidates

The vaccines produced promising preliminary results in phase 1 trials

- PMLiVE

BioNTech and UK government partner to accelerate mRNA cancer immunotherapies

The partnership hopes to provide personalised therapies for up to 10,000 patients

- PMLiVE

bluebird bio sells second FDA priority review voucher for $95m

The company sold its first voucher to Dutch biotech Argenx for $102m

Intelligent and powerful Data/Publication Dissemination with Read, by QxMD

You can get more information on QxMD Read here.  Or contact us directly to discuss here.

Medscape Medical Affairs

You’re sitting on a time bomb, so think harder and give more!

A new philosophy for a new age?

Page & Page Health

- PMLiVE

Amgen and Synaffix sign licensing agreement worth up to $2bn

Amgen will gain access to Synaffix' proprietary antibody-drug conjugates technologies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links